Hutchison China MediTech Limited (HCM) PT Raised to $38.00

Hutchison China MediTech Limited (NASDAQ:HCM) had its price objective boosted by equities research analysts at Canaccord Genuity to $38.00 in a research report issued to clients and investors on Monday, October 16th. The firm presently has a “buy” rating on the stock. Canaccord Genuity’s price objective suggests a potential upside of 24.02% from the stock’s previous close.

Separately, BidaskClub raised shares of Hutchison China MediTech Limited from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 13th.

Hutchison China MediTech Limited (NASDAQ:HCM) opened at 30.64 on Monday. Hutchison China MediTech Limited has a 12 month low of $11.40 and a 12 month high of $32.03. The firm has a market cap of $3.72 billion, a price-to-earnings ratio of 289.06 and a beta of -1.89. The stock’s 50 day moving average is $27.78 and its 200-day moving average is $27.78.

COPYRIGHT VIOLATION WARNING: “Hutchison China MediTech Limited (HCM) PT Raised to $38.00” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/canaccord-genuity-increases-hutchison-china-meditech-limited-hcm-price-target-to-38-00.html.

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC bought a new position in shares of Hutchison China MediTech Limited in the first quarter worth approximately $618,000. The Manufacturers Life Insurance Company grew its holdings in shares of Hutchison China MediTech Limited by 7.7% in the second quarter. The Manufacturers Life Insurance Company now owns 103,799 shares of the company’s stock worth $2,420,000 after purchasing an additional 7,400 shares during the last quarter. Baillie Gifford & Co. grew its holdings in shares of Hutchison China MediTech Limited by 6.1% in the second quarter. Baillie Gifford & Co. now owns 167,547 shares of the company’s stock worth $3,905,000 after purchasing an additional 9,655 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of Hutchison China MediTech Limited in the second quarter worth approximately $5,102,000. Finally, Wellington Management Group LLP grew its holdings in shares of Hutchison China MediTech Limited by 7.4% in the first quarter. Wellington Management Group LLP now owns 510,826 shares of the company’s stock worth $10,190,000 after purchasing an additional 35,053 shares during the last quarter. Hedge funds and other institutional investors own 4.06% of the company’s stock.

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply